Peg-Modified Uricase

Abstract

The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.

Description

FIELD OF THE INVENTION [0001] The present invention is directed to uricase modified with polyethylene glycol and to methods for treating number of different illnesses characterized by increased circulating uric acid levels. BACKGROUND OF THE INVENTION [0002] Uric acid is a product of purine metabolism in birds, reptiles, and primates, including humans. Uric acid is produced in the liver by oxidation of xanthine and hypoxanthine. Xanthine is an intermediate in the catabolism of guanine nucleotides while hypoxanthine is produced during the breakdown of adenine nucleotides. In most mammals, uric acid is further oxidized by the enzyme urate oxidase to allantoin. Allantoin, because of its lost pyrimidine ring, shows a more than 20 times greater water solubility than uric acid. [0003] Urate oxidase, also called uricase, is an enzyme of the purine degradation pathway. Uricase catalyzes the conversion of uric acid+O2 into allantoin+CO2. [0004] Humans lack uricase and do not produce allanton...

AI Technical Summary

Benefits of technology

[0019] In some embodiments the present invention provides methods of enhancing the circulating half life of uricase comprising modifying said uricase by covalently bonding said uricase via a linking group to polyethylene glycol, wherein the polyethylene glycol has a total weight average molecular weight of about 10,000 to about 30,000, and wherein the linking group is selected from the group consisting of a succinimide group, an amide group, an imide group, a carbamate group, an ester group, an epoxy group, a carboxyl group, a hydroxyl group, a carbohydrate, a tyrosine group, a cysteine group, a histidine group and combinations thereof.

[0020] In some embodiments the present invention provides methods of enhancing the anti-uric acid activity of uricase comprising modifying said uricase by covalently bonding said uricase via a linking group to polyethylene glycol, wherein the polyethylene glycol has a total weight average molecular weight of from about 10,000 to about 30,000, and wherein the linking group is selected from the group consisting of a succinimide group, an amide group, an imide group, a carbamate group, an ester group, an epoxy group, a carboxyl group, a hydroxyl group, a carbohydrate, a tyrosine group, a cysteine group, a histidine group and combinations thereof.

Problems solved by technology

Renal handling of uric acid is complex and requires glomerular filtration, reabsorption of filtered urate, tubular secretion, and finally postsecretory reabsorption.

This can result in inflammation of the joints (gout), renal failure, metabolic acidosis, and hyperkalemia.

Hyperuricemia can lead to the loss of kidney function in these patients and can produce significant morbidity and mortality.

However, occasionally cancer patients with a heavy tumor burden may exhibit hyperuricemia and other features of tumor lysis syndrome even in the absence of radiotherapy or chemotherapy because of the high turnover of malignant cells with subsequent catabolism of released purines into uric acid.

Therapy for the prevention and treatment of the acute renal failure associated with tumor lysis syndrome is a considerable challenge and is currently unsatisfactory for a number of reasons.

However, the difficulty in the treatment of hyperuricemia lies in the potential for aggravating other consequences of tumor lysis syndrome.

However, allopurinol does not remove uric acid that is already present and deposited intrarenally as crystals.

However, during excessive catabolism of purines, allopurinol therapy may lead to intrarenal precipitation of hypoxanthine and xanthine, with further aggravation of acute renal failure.

Furthermore, allopurinol therapy is also associated with significant toxicity and can cause death.

Allopurinol can produce severe toxic effects, including cutaneous hypersensitivity reactions, leukopenia, and hepatomegaly.

All of these adverse effects sometimes make allopurinol ineffective for the treatment of acute hyperuricemia in tumor patients.

Thus allopurinol is not an ideal drug for the treatment of hyperuricemia.

However, these treatment methods are problematic in patients with malignancies because of the risk for severe bleeding caused by thrombocytopenia or the need for anticoagulation.

Furthermore, because of the invasive nature of these treatments, there is an increased risk for fatal infections in patients who are in many instances immunocompromised due to their illness or therapy they have received.

Uricase is only available in a few countries, currently limiting the use of this therapy.

Furthermore, none of the uricase treated individuals developed tumor lysis syndrome or required dialysis.

Although oncologists are well aware of the potential advantages of uricase, this therapy has not been widely recognized in the renal community.

An obstacle for a more general application of uricase in hyperuricemia may be the complicated manufacturing process of the enzyme involving fermentation, extraction, and purification, which clearly limits its commercial availability, as well as the standardization of enzyme activity.

While it is possible to obtain highly purified uricase, this method has disadvantages.

Aspergillus flavus is not easy to work with because of its physiology and genetics (WOLOSHUK et. al.

Applied Environ. Microbiol., 55, 86-90, 1989), making it difficult to obtain strains that can produce substantial amounts of the enzyme.

Aspergillus flavus can also produce aflatoxins, which can be difficult to remove during the purification process.

In addition, because of the foreign nature of the Aspergillus enzyme, therapy is many times limited to a single dose due to the risk of hypersensitivity reactions.

Although uricase has been tested in the United States, it is not an approved therapy because of the of a high incidence of allergic reactions to this foreign protein.

The clinical use of uricase is also compromised by its short circulating half-life.